Novartis, a global pharmaceutical company headquartered in Basel, Switzerland, is pursuing new approaches to treating a variety of diseases through the Novartis Institutes for Biomedical Research Biologics Center.

The Biologics Center is located in Basel and Cambridge, MA, and generates therapeutic proteins, antibodies and siRNAs.

The company's leading biologic, developed in collaboration with Genentech, is:

Xolair (bortezomib). Xolair is a recombinant, humanized monoclonal antibody that is used to treat moderate-to-severe persistent asthma in adults and adolescents.

*Information above taken from materials provided by Novartis